Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis

Using a willingness-to-pay threshold of £30 000 per QALY, Sativex® appears unlikely to be considered cost effective by UK funders of healthcare for spasticity in MS. This is unfortunate, since it appears that Sativex® use is likely to benefit some patients in the management of this common consequence of MS. </AbstractSection> Copyright Springer International Publishing AG 2012

MoreLess

Year of publication:	2012
Authors:	Lu, Lanting ; Pearce, Hilary ; Roome, Chris ; Shearer, James ; Lang, Iain ; Stein, Ken
Published in:	PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 30.2012, 12, p. 1157-1171
Publisher:	Springer

Online Resource

Check full text access |

More access options

Check Google Scholar

In libraries world-wide (WorldCat)

In German libraries (KVK)

subito order

I need help

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10011001681